Calithera Biosciences, Inc.
CALAInactive ticker- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496671
No open-market purchases or sales by Calithera Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Calithera Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Calithera Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | Other: Former 10% Owner | – | May 26, 2023 | 0 |
| Takeda Ventures, Inc. | 10% Owner | – | May 26, 2023 | 0 |
| Pakianathan Deepika | Director | 0Indirect | Jan 31, 2023 | 0 |
| Sjogren Eric | SR. VP, DRUG DISCOVERY | 8,467 | Jan 25, 2023 | 0 |
| Kuriakose Emil | CHIEF MEDICAL OFFICER | 3,539 | Jan 25, 2023 | 0 |
| Molineaux Susan | PRESIDENT & CEO | 27,859Indirect | Jan 25, 2023 | 0 |
| Wong Stephanie | See Remarks | 6,287 | Jan 25, 2023 | 0 |
| Molineaux Christopher | SR. VP, DEVELOPMENT | 27,859Indirect | Jan 25, 2023 | 0 |
| Wolff Henry Ward | Director | – | Jun 3, 2022 | 0 |
| Garland J. Scott | Director | – | Jun 3, 2022 | 0 |
| Agarwal Sunil | Director | – | Jun 3, 2022 | 0 |
| Wise Blake | Director | – | Jun 3, 2022 | 0 |
| Orford Keith | Director | 66,094 | Jun 3, 2022 | 0 |
| Jones Suzy | Director | – | Jun 3, 2022 | 0 |
| Ray Sumita | See Remarks | 105,000 | Jan 27, 2022 | 0 |
| Parlati Francesco | SR. VP, RESEARCH | 140,998 | Jan 27, 2022 | 0 |
| Drachman Jonathan G | Director | 200,000 | Nov 10, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 (view filing)7:04 PM ET | Jan 27 | 4 days | Pakianathan DeepikaDirector | SSale | −121.3K | $0.3858 | −$46.8K | −100.0%0 after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Orford KeithDirector | SSale | −78.2K | $0.8723 | −$68.2K | −54.2%66.1K after | 2 lots |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Molineaux SusanPRESIDENT & CEO | PPurchase | +100.0K | $0.85 | +$85.0K | +21.9%557.2K after | Duplicate filing |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Drachman Jonathan GDirector | PPurchase | +200.0K | $0.86 | +$172.0K | New position200.0K after | |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Molineaux ChristopherSR. VP, DEVELOPMENT | PPurchase | +100.0K | $0.85 | +$85.0K | +21.9%557.2K after | |
| Nov 9, 2021 (view filing) | Nov 9 | Same day | Orford KeithDirector | SSale | −51.8K | $0.84 | −$43.5K | −26.4%144.3K after |